Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBITDA Margin (2016 - 2025)

Abeona Therapeutics (ABEO) has 13 years of EBITDA Margin data on record, last reported at 27213.75% in Q2 2025.

  • For Q2 2025, EBITDA Margin changed N/A year-over-year to 27213.75%; the TTM value through Sep 2025 reached 20611.0%, changed N/A, while the annual FY2023 figure was 1546.43%, 153561.0% up from the prior year.
  • EBITDA Margin reached 27213.75% in Q2 2025 per ABEO's latest filing, up from 476.69% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 88115.09% in Q4 2021 and bottomed at 6371.97% in Q1 2022.
  • Average EBITDA Margin over 4 years is 11781.31%, with a median of 1014.07% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: surged 8864359bps in 2021, then crashed -9253862bps in 2022.
  • A 4-year view of EBITDA Margin shows it stood at 88115.09% in 2021, then tumbled by -105bps to 4423.53% in 2022, then surged by 89bps to 476.69% in 2023, then surged by 5809bps to 27213.75% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 27213.75% in Q2 2025, 476.69% in Q2 2023, and 4423.53% in Q4 2022.